GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001593114 | Oral cavity | OSCC | nucleobase-containing compound transport | 150/7305 | 222/18723 | 4.86e-18 | 5.04e-16 | 150 |
GO:006219720 | Oral cavity | OSCC | cellular response to chemical stress | 204/7305 | 337/18723 | 6.89e-16 | 5.19e-14 | 204 |
GO:007121416 | Oral cavity | OSCC | cellular response to abiotic stimulus | 186/7305 | 331/18723 | 1.38e-10 | 4.10e-09 | 186 |
GO:010400416 | Oral cavity | OSCC | cellular response to environmental stimulus | 186/7305 | 331/18723 | 1.38e-10 | 4.10e-09 | 186 |
GO:00069706 | Oral cavity | OSCC | response to osmotic stress | 50/7305 | 84/18723 | 1.11e-04 | 8.15e-04 | 50 |
GO:0051259 | Oral cavity | OSCC | protein complex oligomerization | 121/7305 | 238/18723 | 1.29e-04 | 9.21e-04 | 121 |
GO:00714706 | Oral cavity | OSCC | cellular response to osmotic stress | 26/7305 | 41/18723 | 1.34e-03 | 6.62e-03 | 26 |
GO:19012642 | Oral cavity | OSCC | carbohydrate derivative transport | 44/7305 | 80/18723 | 2.67e-03 | 1.16e-02 | 44 |
GO:001593121 | Oral cavity | EOLP | nucleobase-containing compound transport | 58/2218 | 222/18723 | 3.44e-09 | 2.10e-07 | 58 |
GO:006219726 | Oral cavity | EOLP | cellular response to chemical stress | 64/2218 | 337/18723 | 8.49e-05 | 1.01e-03 | 64 |
GO:1901679 | Oral cavity | EOLP | nucleotide transmembrane transport | 8/2218 | 20/18723 | 1.29e-03 | 9.17e-03 | 8 |
GO:00157483 | Oral cavity | EOLP | organophosphate ester transport | 28/2218 | 140/18723 | 3.66e-03 | 2.05e-02 | 28 |
GO:0006862 | Oral cavity | EOLP | nucleotide transport | 10/2218 | 37/18723 | 9.12e-03 | 4.15e-02 | 10 |
GO:006219733 | Oral cavity | NEOLP | cellular response to chemical stress | 75/2005 | 337/18723 | 4.87e-10 | 3.97e-08 | 75 |
GO:001593131 | Oral cavity | NEOLP | nucleobase-containing compound transport | 48/2005 | 222/18723 | 1.51e-06 | 3.77e-05 | 48 |
GO:007121424 | Oral cavity | NEOLP | cellular response to abiotic stimulus | 55/2005 | 331/18723 | 6.38e-04 | 5.43e-03 | 55 |
GO:010400424 | Oral cavity | NEOLP | cellular response to environmental stimulus | 55/2005 | 331/18723 | 6.38e-04 | 5.43e-03 | 55 |
GO:19016791 | Oral cavity | NEOLP | nucleotide transmembrane transport | 7/2005 | 20/18723 | 3.51e-03 | 2.06e-02 | 7 |
GO:001574811 | Oral cavity | NEOLP | organophosphate ester transport | 25/2005 | 140/18723 | 7.16e-03 | 3.63e-02 | 25 |
GO:007147014 | Oral cavity | NEOLP | cellular response to osmotic stress | 10/2005 | 41/18723 | 9.71e-03 | 4.55e-02 | 10 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LRRC8C | SNV | Missense_Mutation | | c.304G>C | p.Asp102His | p.D102H | Q8TDW0 | protein_coding | tolerated(0.08) | possibly_damaging(0.873) | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
LRRC8C | SNV | Missense_Mutation | novel | c.1444C>T | p.His482Tyr | p.H482Y | Q8TDW0 | protein_coding | deleterious(0) | benign(0.424) | TCGA-A2-A3XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PR |
LRRC8C | SNV | Missense_Mutation | rs751573376 | c.10N>A | p.Val4Met | p.V4M | Q8TDW0 | protein_coding | deleterious(0.01) | possibly_damaging(0.529) | TCGA-A7-A13D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
LRRC8C | SNV | Missense_Mutation | novel | c.529N>C | p.Glu177Gln | p.E177Q | Q8TDW0 | protein_coding | deleterious(0) | benign(0.213) | TCGA-A8-A079-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
LRRC8C | SNV | Missense_Mutation | novel | c.1292T>C | p.Ile431Thr | p.I431T | Q8TDW0 | protein_coding | deleterious(0.02) | benign(0.017) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LRRC8C | SNV | Missense_Mutation | novel | c.173N>C | p.Arg58Thr | p.R58T | Q8TDW0 | protein_coding | tolerated(0.34) | benign(0.005) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
LRRC8C | SNV | Missense_Mutation | | c.293G>A | p.Gly98Asp | p.G98D | Q8TDW0 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LRRC8C | SNV | Missense_Mutation | | c.2237C>A | p.Pro746Gln | p.P746Q | Q8TDW0 | protein_coding | deleterious(0.02) | possibly_damaging(0.734) | TCGA-D8-A27M-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | methotrexate+5 | SD |
LRRC8C | SNV | Missense_Mutation | rs200185887 | c.1492G>A | p.Val498Ile | p.V498I | Q8TDW0 | protein_coding | tolerated(0.34) | benign(0.211) | TCGA-E9-A1R6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
LRRC8C | SNV | Missense_Mutation | | c.2407N>C | p.Glu803Gln | p.E803Q | Q8TDW0 | protein_coding | tolerated(0.05) | probably_damaging(0.947) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |